
GLP-1 Drugs Show Promise in Lowering Health Care Costs, Report Says
The growing use of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide (Ozempic, Wegovy; Novo Nordisk) and tirzepatide (Mounjaro; Eli Lilly and Co.)—is contributing to lower overall medical costs among patients who remain on the …